Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jill Lacy

Showing results (51-60 of 59) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 59 results.
The Oncologist|July 18, 2024
Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinomaGregory P Botta, Maen Abdelrahim, Ronald L Drengler, et al.
The Journal of Clinical Investigation|December 15, 2021
Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancersMark Yarchoan, Leslie Cope, Amanda N Ruggieri, et al.
JAMA Oncology|June 20, 2024
Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer: A Nonrandomized Controlled TrialMichael Cecchini, Ronald R Salem, Marie Robert, et al.
Oncology (Williston Park, N.Y.)|April 27, 2023
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal AdenocarcinomaDaniel Vt Catenacci, Yoon-Koo Kang, Hope E Uronis, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 4, 2023
Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in OncologyJaffer A Ajani, Thomas A D'Amico, David J Bentrem, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 7, 2022
Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in OncologyJaffer A Ajani, Thomas A D'Amico, David J Bentrem, et al.
The Lancet. Oncology|July 13, 2020
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trialDaniel V T Catenacci, Yoon-Koo Kang, Haeseong Park, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 9, 2025
Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In OncologyJaffer A Ajani, Thomas A D'Amico, David J Bentrem, et al.
Journal of the National Cancer Institute|May 16, 2019
Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-AnalysisQuisette P Janssen, Stefan Buettner, Mustafa Suker, et al.
Pageof 6

Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
The Oncologist|July 18, 2024
Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinomaGregory P Botta, Maen Abdelrahim, Ronald L Drengler, et al.
The Journal of Clinical Investigation|December 15, 2021
Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancersMark Yarchoan, Leslie Cope, Amanda N Ruggieri, et al.
JAMA Oncology|June 20, 2024
Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer: A Nonrandomized Controlled TrialMichael Cecchini, Ronald R Salem, Marie Robert, et al.
Oncology (Williston Park, N.Y.)|April 27, 2023
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal AdenocarcinomaDaniel Vt Catenacci, Yoon-Koo Kang, Hope E Uronis, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 4, 2023
Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in OncologyJaffer A Ajani, Thomas A D'Amico, David J Bentrem, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 7, 2022
Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in OncologyJaffer A Ajani, Thomas A D'Amico, David J Bentrem, et al.
The Lancet. Oncology|July 13, 2020
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trialDaniel V T Catenacci, Yoon-Koo Kang, Haeseong Park, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 9, 2025
Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In OncologyJaffer A Ajani, Thomas A D'Amico, David J Bentrem, et al.
Journal of the National Cancer Institute|May 16, 2019
Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-AnalysisQuisette P Janssen, Stefan Buettner, Mustafa Suker, et al.
Pageof 6